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The  rationale behind attemDts to select ~at ients .  However. if the matching of anti- 
= (~amdurke; ct aL, 1962: ~ k e n t  a i d  hleda- Ymportant role in long-term survhal; a dis- 
- - - - - - - - , - - - - , 
et al., 1964a). How this might be .accom- trend wa; obtain&. 
lished is the immediate concern of this con- it: 
rerence. In this preliminary study we have : .' 
Methods L investigated the possibility of using allogenic 
antisera derived from women with multiple t k  i I a 
If Denver was flown to Los AngelesT Viable As the initial step in testing the efficacy of lymphocytes were isolated within 12 hr  from the lymphocyte cytotoxic reaction as a typing the time of bleeding. The method of isola- orncedure for homotrans~lantation. long- tion consisted of differential adherence of r - -  
term kidney homograft sirvivors and theyr granulocytes on a polystyrene surface fol- 
donors were tested for compatibility. If for- lowed by centrifugation in capillary tubes to 
tuitous matching of transplantation antigens eliminate most of the erythrocytes (Terasaki 
had hren ~ r i n c i ~ a l l v  res~onsible for the el  al., in press; Terasaki and McClelland. 
patibilit; should be evident f r o g  the typing different human antisera. The sera were ob- 
~ t i i d i ~ ~  Preri~e corrclatinn of survival time tained mainlv from women with multiple 
- ---- 
-1 r - -0 
. since the method of immunosuppressibn was tained from mblt$le transfusions (#2, 6, 
regulated by the clinical course of individual and 15), and two from persons immunized by 
---- - . .  ' , , 
long survival of renal transplants in these submitted for publication). Lymphocyte anti- 
selected ~at ients ,  a reasoiable demee of com- zens were identified by cytotoxicity of 50 I 
" .--.- ". - - ----- ---. -- . . 
with t v o i n ~  methods cannot be ex~ected, abortions and premancies; a few were bb- m 
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6283, A-63h. HE-07735, Ahf-Oi'ii2, AI-01452. and b ~ - 2 7 ,  and a USPHS research 
career program award AM-7513 from the National Institute of Arthritis and Meta- 
bolic Diseases. 

three or four consecutive skin homografts 
(#22 and 24): Antisera #15, 27, and 14 
were from habitual aborters .** 
The microdroplet oil chamber method of 
testing has been described (Terasaki and Mc- 
Clelland, submitted for publication). Essen- 
tially, mixtures of 2,000 lymphocytes, 0.003 
ml of absorbed rabbit complement, and anti- 
body dilutions by thirds from 0.003 to 0.00003 
ml were incubated for 4 hr at room tempera- 
ture. The microreactions were accompl~shed 
in an oil chamber and assayed by counting 
the percentage of viable cells under phase- 
contrast microscopy at 620 x or 820 x mag- 
nification. 
Erythrocytes were typed with standard com- 
mercial antisera, using the Coulter Counter 
to measure agglutination (Terasaki et al., in 
press). 
Results 
Red-cell antigens. Many of the long-term 
surviving kidney homograft patients have 
survived despite one to three "minor" erythro- 
cyte-group ~ncompatibilities with their re- 
spective donors (Fig. 1). Most erythrocyte 
groups seemed innocuous, for incompatibili- 
ties were noted with E, Fy', M. C, D, s, and 
c. Among the limited numbers of survivors 
tested, no incom atibilities were found for 
A, B, N, or e. ~ [ e  fact that eight out of I1 
of the 6-months-or-longer group possessed 
one incompatibility or none may suggest. 
however, that multiple incompatibilities may 
be deleterious. On the other hand, since 
two of the longest survivors had two or three 
incompatibilities, mismatched erythrocyte 
antigens may not be a critical factor to sur- 
vival of the graft. In patient #4, in whom 
there was a C and D mismatch, 10 months 
after transplantation antibodies were de- 
tected against donor erythrocytes. If it is 
assumed that no transfusions of Rh+ blood 
were given, these antibodies may have been 
elicited by antigens in the donor kidney. 
The fact that the kidney is functioning 10 
months after transplantation demonstrates 
that the presence of such antibodies is not 
clinically deleterious to the kidney graft. 
Similar tests on papainized erythrocytes of 
the donor with the plasma of recipients #1, 
2, 12, 14, 13, and 10 were negative. In  these 
Kindly contributed by Dr. Roy Walford; #22 and 24 are designated Bu and Mo. 
respectively, in Walford, Galla her, and Sjaarda (1964) . 
** Generously contributed by %r. Phillip Levine. 
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Figure 1.-Erythrocyte-group incompatibilities between kidney homognft donors 
and their recipients are shown in the dark ban. 
planted from a brother to sister, remained proper diagnosis and tlierapy of "rejection" 
anuric for 2 weeks, after which it was re- crises, are essential (Starzl et al., 1964b). A 
moved. Tests of the recipient's serum before lesser degree of matching presumably would 
grafting revealed cytotoxlc antibodies against have led to rapid rejection. The possibility 
the donor's lymphocytes. Serum taken on that the apparent correspondence was merely 
the day of transplantation just before graft- the result of similar but nonspecific reactions 
ing was cytotoxic to 70 percent of cells (using of the antisera was tested by comparing the 
0.003 ml of serum, 0.005 ml of C', and 2,000 typing reactions of random hypothetical 
lymphocytes) and became slightly less toxic 2 donors with the donor actually used. In  
and 6 days after grafting. These antibodies most instances, the actual donor was found 
could have been elicited by transfusions and to be one of the better donors with few in- 
may be suspected of being responsible for compatibilities, whereas many other donors 
the immediate rejection. possessed numerous antigens in excess of the 
recipient (Table 3). Of considerable sig- 
Discussion nificance is the fact that for some recipients a nonrelated individual was an even more 
suitable donor than the close relative used. 
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Figure 3.-Lymphocyte-cytotoxicity titration of a donor (wife) and unrelated 
recipient (#7). The resultr are plotted as in Fig. 2. Of particular interest is 
the fact that the donor possessed only one antigen that the recipient did not, 
whereas a graft in the opposite direction would have been incompatible for 
An incompatibility in which the donor re- saki, submitted for publication; Terasaki 
acts with a given antiserum and the recipient et al., in press). Van Rood has earlier en- 
does not is not open to the same polyvalent- countered a similar phenomenon with leuko- 
antiserum criticism. Cells of the donor may agglutinins which he termed agglutination- 
react on the basis of A, B, C, . . . Z antigens, negative-absorption-positive reaction van 
whereas the recipient can be taken to lack Rood and van Leeuwen. 1963), and similar 
all these antigens from a negative reaction. reactions have been found with erythrocytes 
This type of incompatibility, however, does (Race and Sanger, 1962). Absorption experi- 
suffer from another difficulty, in that a non- ments may therefore be essential to prove 
reactive cell may be capable at times of that an antigen is lacking, for the amount of 
absorbing out cytotoxicity (Becker and Tera- antigen present may be sufficient to absorb 
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culties of non-specific agglutination found 
with leukoagglutination tests (van Rood, 
van Leeuwen, and Bosch, 1962; Dausset, 
1962). The present miaodroplet technique 
permits performance of numerous tests with 
extremely small quantities of rare human 
antisera. Moreover, since lymphocytes are 
H I S T O C O M P A T  ~ B I L I T Y  T E S T I N G  
of "minor" erythrocyte g ~ o u p s  i n  trans- following transplantation were tested for 
plantation is given by Rogers (1963). From compatibility with their respective donors. 
the present initial trials, survival for more T h e  degree of incompatibility expressed in 
than 6 months was obtained in spite of terms of numbers o r  units of mismatched 
incompatibilities with E, Fy', M, C, D, s, and  antigens was relatively small when compared 
c (Fig. 1). Perhaps some significance could with that of hypothetical grafts from unre- 
be attached to the fact that seven out  of lated donors typed by the same methods. 
10 long-term survivors (10 t o  18 months) Though many improvements in  the typing 
possessed two or three antigen incompatibil- system remain to  be made, it  is suggested 
rties. Moreover, i n  one patient, anti-CD that with further experience, this method of 
antibodies were found together with good histocompatibility typing may be.practicable 
renal function 10 months after grafting. T h e  in uncovering major transplantation "types." 
conclusion which might be indicated is that 
matching of "minor" erythrocyte antigens 
may increase the chance of success, though Acknowledgments 
complete matching may not be obligatory. 
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Discussion rather long-term survivor that had many in- 
compatibilities with the donor lymphocytes 
DR. CEPPELLINI: What is the repre by your typing method. 
ducibility of your test? 
H I i T O C O M P A T I B I L 1 T Y  TEST I N C  
TABLE 1 
Lymphocyte Cytotoxicity in Relation to Time of Skin Grafting and 
Leukocyte Injection. Skin Grafts at Approximately 36-day Intervals; 
Leukocyte Injection 210 Days After Last Graft. 
Titer of Recipient Serum vs. Donor Lymphocytes 
Serum Specimen 
1:2 1:8 192 1:128 1312 1:2048 
- - - - - -  
I4 days after 1st set 
14 days Pfter 2nd ~t 
15 days after 3rd set 80 50 14 
12 days after 4th set 86 70 14 
7 days dkerlcukocyte injection 95 61 58 67 51 
